Community rallies behind local man seeking kidney donor at ‘Adam's March for a Match'
NORTHAMPTON, Mass. (WWLP) – People from all over western Massachusetts came together to support a local man in his battle with kidney failure.
Friends, family, and the community gathered at Look Park on Sunday for Adam's March for a Match, walking to support Adam Gagne as he battles Stage 5 kidney failure.
'Groovin' with Garrett' fundraiser for local man who was paralyzed in skiing accident
'I created a video telling his story and what we needed, and then I worked with two of his really good friends, longtime friends, Sue and Eric Dibrinkisi,' said David Jeffway, Adam's March for a Match organizer. 'We decided we needed to rally the community behind him because he has been such a big part of this community.'
Adam was unable to be in attendance, as he has been in the hospital due to complications, but he was present on a video call. People were able to speak with Adam, sharing how he impacted their lives and adding written messages to his support board.
Adam Gagne made a huge impact on his community, as he served as Scout Master for over 30 years. Now his scouts throughout the years are giving back to him.
'Scouting and obtaining that rank of Eagle is all about giving back and helping other people at all times, which is part of the Scout oath,' said Jeffway, who served as an Eagle Scout under Gagne. 'This is all of that on display. It is not just through the words, it's exactly what we learned in scouting.'
The event was also catered by Jake's in Northampton. The restaurant's owners, Christopher Ware and Alexander Washut, were also Eagle Scouts under Gagne.
'He was like an older brother, more so than a Scout Master, if you will,' Ware said. 'It was really a great time in our lives, so when we heard he needs this kidney, we thought we want to help him any way we could.'
Jeffway said the goals of the event are to find a living donor, raise money for Gagne and his family, and show him just how many people care about him. For more information on how you can become a living donor and test to see if you are a match for Adam, visit baystatehealth.org/living-donor.
WWLP-22News, an NBC affiliate, began broadcasting in March 1953 to provide local news, network, syndicated, and local programming to western Massachusetts. Watch the 22News Digital Edition weekdays at 4 p.m. on WWLP.com.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
BioPorto A/S Announces the Appointment of a New CEO as Part of its Succession Planning Strategy
June 10, 2025Announcement no. 16 BioPorto A/S Announces the Appointment of a New CEO as Part of its Succession Planning Strategy COPENHAGEN, DENMARK and BOSTON, MA, USA, June 10, 2025, (GLOBE NEWSWIRE) - BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR) today announced the appointment of Carsten Buhl as Chief Executive Officer (CEO) of BioPorto A/S and its subsidiaries, effective 1 September 2025, as part of the Company's succession planning strategy. BioPorto's current CEO, Peter Mørch Eriksen, will remain in his position until 1 September 2025. Following this date, Peter Mørch Eriksen will support the incoming CEO during the transition period to ensure a smooth and effective onboarding process. Carsten Buhl has spent more than 25 years in the MedTech/life science industries, recently as President of Americas at WSAudiology and part of its executive management. Further, Carsten has experience from senior leadership positions at Natus Medical Inc, Ambu and GN Store Nord. Jens Due Olsen, Chair of BioPorto, stated: "I am pleased to welcome Carsten Buhl to BioPorto. Carsten will be instrumental in launching ProNephro AKI (NGAL)™ in the US market, driving revenue growth and finalizing the clinical studies & submitting an FDA application for adult use in 2026. With a strong background in MedTech/life science, Carsten has a proven track record of driving growth, innovation, and operational excellence. Carsten will be a solid addition to the BioPorto team.' Carsten Buhl, BioPorto's incoming CEO, commented: 'I am excited to join BioPorto at this amazing point in its journey, and look forward together with the BioPorto team to materialize the full potential of the Company's biomarker tests within kidney health, critical tests that can improve the clinical and economic outcomes for patients, providers, and healthcare ecosystem globally." Jens Due Olsen added: 'I want to extend my gratitude to and thank Peter for his dedication and important contributions to BioPorto. During this second tenure, significant milestones have been achieved — including the development of a comprehensive Corporate Strategy Plan, securing revenue growth, preparation for the commercial launch of ProNephro AKI (NGAL) in the US, advancement of the clinical trial for adult use, and securing successive critical financing rounds for the Company. These accomplishments have laid a robust foundation for BioPorto's continued growth and success.' To receive BioPorto's Company Announcements, Press Releases, Newsletters and other business relevant information, please sign up on Investor Relations Contacts Hanne S. Foss, Head of Investor Relations, BioPorto A/S, investor@ C: +45 26368918 About BioPorto BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company's tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem. The Company's flagship products are based on the NGAL biomarker and designed to aid in the risk assessment and diagnosis of Acute Kidney Injury, a common clinical syndrome that can have severe consequences, including significant morbidity and mortality, if not identified and treated early. With the aid of NGAL levels, physicians can identify patients potentially at risk of AKI more rapidly than is possible with current standard of care measurements, enabling earlier intervention and more tailored patient management strategies. The Company markets NGAL tests under applicable registrations including CE mark in several countries worldwide. BioPorto has facilities in Copenhagen, Denmark and Boston, MA, USA. The shares of BioPorto A/S are listed on the Nasdaq Copenhagen stock exchange. For more information visit Forward looking statement disclaimer Certain statements in this news release are not historical facts and may be forward-looking statements. Forward-looking statements include statements regarding the intent, belief or current expectations with respect to the Company's expectations, intentions and projections regarding its future performance including the Company's Guidance for 2025; currency exchange rate fluctuations; anticipated events or trends and other matters that are not historical facts, including with respect to implementation of manufacturing and quality systems, commercialization of NGAL tests, and the development of future products and new indications; concerns that may arise from additional data, analysis or results obtained during clinical trials; and, the Company's ability to successfully market both new and existing products. These forward-looking statements, which may use words such as 'aim', 'anticipate', 'believe', 'intend', 'estimate', 'expect' and words of similar meaning, include all matters that are not historical facts. These forward-looking statements involve risks, and uncertainties that could cause the actual results of operations, financial condition, liquidity, dividend policy and the development of the industry in which the Company's business operates to differ materially from the impression created by the forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Given these risks and uncertainties, prospective investors are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date of such statements and, except as required by applicable law, the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Factors that may impact BioPorto's success are more fully disclosed in BioPorto's periodic financial filings, including its Annual Report for 2024, particularly under the heading 'Risk Factors'. Attachment 2025 06 10 - Announcement no. 16 - UKError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Archaeologists Found a 6,200-Year-Old Skull. Then They Noticed Something Very Wrong.
Here's what you'll learn when you read this story: The burial site Chega Sofla has many skeletons with elongated skulls, likely from a practice called cranial bandaging where people use wrapped fabric to permanently reshape the skull in infancy and early childhood. Researchers discovered one skeleton with a cone-shaped skull that died from blunt force trauma. The study used CT scans to analyze the thickness of the elongated skull and determine whether the severity of the injuries could be attributed to the cranial bandaging. Much to your grandma's dismay, your tattoos and piercings are types of body modifications, or procedures that deliberately alter the human body. Humans have experimented with these alterations for much of our existence. And while your 'sick ink' may be widely accepted in the Western world, other cultures have body modification rituals that are much more extreme by our standards. Cranial bandaging is the practice of wrapping strips of fabric around a child's growing skull to permanently modify the shape. When performed over several years, cranial bandaging results in an elongated, cone-shaped head. Many skeletons with these modified skulls have been found at Chega Sofla, a site in western Iran that dates all the way back to 4,700 B.C. The site features dozens of graves that range in size from single burials to entire family tombs. Researchers for the Zohreh Prehistoric Project have studied the area for more than a decade, and they recently discovered the remains of a woman with an elongated skull that was inexplicably bashed in. Published in the International Journal of Osteoarchaeology on May 22, the researchers' new study details the traumatic head injury that killed the woman about 6,200 years ago. 'We know this woman experienced the fracture in the final moments of her life,' lead author of the study Mahdi Alirezazadeh told Live Science, 'but we don't have any direct evidence to say that someone intentionally struck her.' Alirezazadeh and the other researcher on the study, Hamed Vahdati Nasab, used CT scans to get a closer look at the woman's (referred to as BG1.12 in the study) skull. They focused on the thickness of her cranial bones and something called the diploë, or the spongy bone tissue found between the external and internal calvaria layers (think of diploë as the insulation in the walls of the skull). Researchers found that BG1.12's bones and their diploë were much thinner than that of a typical skull, although they noted that this is to be expected with cranial alterations. They explain that because of the thinness, the skull was likely much less effective at protecting the brain from external forces—like a blunt-force blow—than a normal skull would be. The triangular fracture on BG1.12's skull runs from the front to the left side of her head. According to the study, 'an intense force delivered by an object with a wide edge impacted the skull of this young woman during her final moments.' Alirezazadeh explains that they can't necessarily attribute the woman's death to her modified skull because the trauma was so severe. He also noted that another fractured skull was found at the site, except it was unmodified. 'It should be noted that the blow was so severe that it would have fractured a normal, unmodified skull as well,' the researcher told Live Science. 'So we cannot attribute cranial fractures solely to modified skulls,' he later continued. At Chega Sofla, people with and without cranial modifications are buried together, so the woman's skeleton has yet to be identified. Researchers are also still uncertain whether the woman sustained her injuries accidentally—or if she was murdered. You Might Also Like The Do's and Don'ts of Using Painter's Tape The Best Portable BBQ Grills for Cooking Anywhere Can a Smart Watch Prolong Your Life?
Yahoo
5 hours ago
- Yahoo
3 Reasons to Avoid ICUI and 1 Stock to Buy Instead
Over the last six months, ICU Medical's shares have sunk to $136.25, producing a disappointing 14.9% loss while the S&P 500 was flat. This may have investors wondering how to approach the situation. Is now the time to buy ICU Medical, or should you be careful about including it in your portfolio? Dive into our full research report to see our analyst team's opinion, it's free. Even though the stock has become cheaper, we don't have much confidence in ICU Medical. Here are three reasons why you should be careful with ICUI and a stock we'd rather own. Long-term growth is the most important, but within healthcare, a stretched historical view may miss new innovations or demand cycles. ICU Medical's recent performance shows its demand has slowed as its annualized revenue growth of 2.2% over the last two years was below its five-year trend. Forecasted revenues by Wall Street analysts signal a company's potential. Predictions may not always be accurate, but accelerating growth typically boosts valuation multiples and stock prices while slowing growth does the opposite. Over the next 12 months, sell-side analysts expect ICU Medical's revenue to drop by 12.3%, a decrease from its 14.6% annualized growth for the past five years. This projection is underwhelming and suggests its products and services will face some demand challenges. Analyzing the long-term change in earnings per share (EPS) shows whether a company's incremental sales were profitable – for example, revenue could be inflated through excessive spending on advertising and promotions. Sadly for ICU Medical, its EPS declined by 1.1% annually over the last five years while its revenue grew by 14.6%. This tells us the company became less profitable on a per-share basis as it expanded. We cheer for all companies serving everyday consumers, but in the case of ICU Medical, we'll be cheering from the sidelines. Following the recent decline, the stock trades at 18.9× forward P/E (or $136.25 per share). This valuation tells us a lot of optimism is priced in - you can find better investment opportunities elsewhere. We'd suggest looking at a dominant Aerospace business that has perfected its M&A strategy. Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
